In contrast, G 1 -arrested cells were more sensitive to MAPK pathway inhibitor-induced cell death.
INTRODUCTION

Small molecule inhibitors that selectively target mutant BRAF or its downstream effector MEK
have provided unprecedented responses in a subset of BRAF mutant melanoma patients (McArthur, 2015) . However, development of resistance is common (Homet and Ribas, 2014) .
Therefore, an improved understanding of the underlying biological mechanisms mediating drug M A N U S C R I P T
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4 efficacy and the emergence of resistance is required to develop more effective therapeutic strategies for patients with metastatic melanoma.
MAPK pathway inhibitors (referred to subsequently as MAPKi) effectively induce G 1 -phase cell cycle-arrest (referred to subsequently as G 1 -arrest) and apoptosis Haferkamp et al., 2013; Lee et al., 2010; Tsai et al., 2008) . The 26S proteasome inhibitor, bortezomib, which is approved for treating multiple myeloma and mantel cell lymphoma Orlowski and Kuhn, 2008) , induces apoptosis of melanoma cells through a mechanism involving induction of G 2 /M-arrest (Ling et al., 2003; Selimovic et al., 2013; Tamura et al., 2010) , whilst having minimal adverse effect on melanocytes (Fernandez et al., 2005) . However, while bortezomib induces robust cytotoxicity of proliferating melanoma cells in vitro, the response of melanoma cells to bortezomib is greatly reduced in vivo (Hill et al., 2009) . The DNA-alkylating agent temozolomide, a derivative of dacarbazine, induces DNA damage and G 2 /M-arrest leading to apoptosis in melanoma cell lines in vitro (Eich et al., 2013; Roos et al., 2014) , but has limited efficacy in metastatic melanoma patients (Teimouri et al., 2013) .
Reduced access to oxygen and nutrients in the tumor center or in areas distant from the vasculature causes G 1 -arrest , which can influence the response to chemotherapies that target actively dividing cells (Mitchison, 2012) . Hypoxia induces phenotype switching O'Connell et al., 2013) and a stress response within melanoma cells that confers a drug-tolerant state (Ravindran Menon et al., 2015) . Studies on human lymphocytes revealed that clinically relevant doses of temozolomide only induced apoptosis in proliferating cells (Roos et al., 2004) . These findings highlight that environmental factors within M A N U S C R I P T
5 a tumor and/or cell cycle status may alter the response of melanoma cells to therapies (Haass, 2015) .
To determine the effect of the tumor microenvironment (Brandner and Haass, 2013) and cell cycle status on melanoma response to bortezomib, temozolomide, MAPKi or combinations of these drugs, we utilized the fluorescent ubiquitination-based cell cycle indicator (FUCCI) (Sakaue-Sawano et al., 2008) in three melanoma cell lines to track the cell cycle in 2D-cultured cells or within 3D collagen-embedded spheroids . This model allowed us to study the effect of the cell cycle on drug sensitivity in real-time. We found that both pharmacologically and environmentally G 1 -arrested melanoma cells are resistant to bortezomib and temozolomide-induced cytotoxicity, but are sensitized to MAPK inhibition -a finding that has implications on the choice and timing of drug combination therapies.
RESULTS
Bortezomib induces dose-dependent G 2 -arrest of melanoma cells.
To track the cell cycle status in melanoma cell lines, we utilized FUCCI in which red fluorescence indicates G 1 , yellow early S, and green S/G 2 /M-phases, with a short loss of fluorescence just after division Sakaue-Sawano et al., 2008) .
Bortezomib induces G 2 -arrest of cancer cells, including melanoma (Bavi et al., 2011; Hill et al., 2009; Hong et al., 2012; Ling et al., 2003; Yin et al., 2005) . Consistently, flow cytometry and image analysis of DAPI-stained FUCCI-C8161, -WM164 and -1205Lu cells demonstrated dosedependent G 2 -phase accumulation after 24h bortezomib treatment in 2D culture (Figure 1a Figure S1a ,b). G 2 -arrested cells appeared yellow (rather than green), which is likely due to inhibition of proteasomal degradation of the fluorescent reporters by bortezomib (Wohlschlegel et al., 2000) . There was a significant dose-dependent inhibition of cell viability/proliferation after 48h bortezomib treatment (Figure 1c and Supplementary Figure S1c ).
These data confirm that bortezomib causes dose-dependent G 2 -arrest of melanoma cells. Figure S2) . However, the G1-arrested spheroid core, a result of hypoxia and nutrient deprivation Figure S3b) , with very few cells completing mitosis after addition of the drug (mean of 18% for C8161, 3.5% for 1205Lu, compared to 100% in the controls). Of the bortezomib-treated cells that stayed alive, 13% (C8161) or 84% (1205Lu) remained in G 1 (FUCCI-red) for the entire observation period (40h), compared to 0.5% (C8161) and 3% (1205Lu) in the controls, confirming that a subset of cells undergo G 0 /G 1 -arrest in response to bortezomib. Single cell tracking showed that while cells in both G 1 -and G 2 -phase died, more M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 green/yellow S/G 2 /M-phase cells died than red G 1 cells (Figure 3b) and that S/G 2 /M-phase cells died significantly earlier than G 0 /G 1 -phase cells (Figure 3c ).
Annexin V-staining of FUCCI-C8161 and -1205Lu cells after bortezomib treatment indicated the mode of cytotoxicity was primarily apoptosis (Figure 3d, Supplementary Figure S3c) . The majority of apoptotic cells were in S/G 2 /M-phase, and the proportion of apoptotic cells increased over time. Apoptotic G 1 -phase cells were also observed, although the proportion was significantly lower and apoptosis was delayed compared to S/G 2 /M-phase cells. These results, together with the imaging data, indicate that bortezomib causes G 2 -and G 1 -arrest, and that melanoma cells in G 1 -phase are less sensitive to bortezomib-induced apoptosis.
As the pro-apoptotic protein NOXA promotes bortezomib-mediated apoptosis in melanoma (Fernandez et al., 2005; Mohana-Kumaran et al., 2014; Podar et al., 2008; Qin et al., 2005; Reuland et al., 2012; Wolter et al., 2007) , we chose to investigate if NOXA was also involved in cell-cycle specific bortezomib-mediated apoptosis. 
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Bortezomib-induced G 1 -arrest is reversible
As bortezomib is a reversible inhibitor , we wished to determine if bortezomibinduced G 1 -arrest is also reversible. To test whether bortezomib-treated G 1 -arrested cells can reenter the cell cycle after drug removal, we treated 2D-cultured FUCCI-C8161 and -1205Lu cells for three days, then changed to normal medium. Time-lapse imaging indicated that G 1 -arrested cells re-entered the cell cycle after bortezomib removal (Supplementary Figure S3d 
Pharmacologically induced G 1 -arrest inhibits bortezomib and temozolomide-induced cytotoxicity
Resistance of G 1 -arrested cells in the spheroid core to bortezomib-induced G 2 -arrest, as well as the longer survival of G 1 -arrested bortezomib-treated cells, indicates that G 1 -arrested cells are less sensitive to bortezomib-induced apoptosis. To investigate this theory further, melanoma cells were pre-treated with G 1 -arrest inducing drugs before exposure to bortezomib (Figure 4a ). We have demonstrated previously that MEK or BRAF inhibition induces G 1 -arrest Haass et al., 2008) . Therefore, C8161, WM164 and 1205Lu cells in either 2D or 3D culture were treated for 24h with the MEK inhibitor U0126 or the selective BRAF inhibitor PLX4032 at a concentration that was optimized for each cell line to induce G 1 -arrest without significant cell death (Supplementary Figure S4a 
C8161 is BRAF
WT at codon 600 (Davies et al., 2009 ) and therefore does not undergo G 1 -arrest in response to PLX4032 (Lee et al., 2010) . Unsurprisingly, PLX4032 did not cause G 1 -arrest in C8161 (Supplementary Figure S4c) . This may be due to off-target effects of PLX4032 or the paradoxical activation of MAPK in BRAF WT cells (Hatzivassiliou et al., 2010) . Typically, pERK was slightly increased after 48h PLX4032 treatment in C8161 cells (either alone or in combination with bortezomib). However bortezomib alone did not significantly alter pERK levels (data not shown).
To confirm that G 1 -arrest inducing pre-treatment was necessary for the rescue effect in BRAFmutant WM164 cells, we added PLX4032 simultaneously with bortezomib. Indeed there was no rescue from bortezomib-induced apoptosis (Figure 4f ). However, as both drugs alone induced some cell death and the combination had no additive effect, there was possibly some protection from bortezomib-mediated apoptosis. Some cells may undergo PLX4032-induced G 1 -arrest M A N U S C R I P T
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To determine if pharmacologically induced G 1 -arrest can rescue MAPKi cytotoxicity, we pretreated WM164 cells with low-dose PLX4032 to cause G 1 -arrest but minimal cytotoxicity, then treated with U0126 for further 48h (Figure 4g ). Although the amount of cell death was similar between single-agent PLX4032 and U0126 treatments, there was a significant increase in cell death for the combination. This suggests that rather than rescuing cells from U0126-induced cell death, PLX4032-induced G 1 -arrest sensitizes cells to U0126-induced cell death.
To explore if pharmacologically induced G 1 -arrest protected from G 2 -arrest inducing drugs other than bortezomib, we tested the effect of U0126 pre-treatment on temozolomide-induced cytotoxicity. Temozolomide caused G 2 -arrest of C8161 after 24h treatment (Figure 4h ). U0126
pre-treatment protected cells from temozolomide-induced G 2 -arrest and cell death (Figure 4i , Supplementary Figure S4g ). WM164 and 1205Lu were resistant to temozolomide. At the high concentrations required to induce cell death (>100 µM), very little G 2 -arrest was observed.
Melanoma cell resistance to temozolomide has been described previously (Mhaidat et al., 2007) .
Finally, to determine the effect of G 2 -arrest on MAPKi cytotoxicity we pre-treated C8161 cells with low-dose temozolomide, then added high-dose U0126 for further 48h to induce cell death.
In this case the cells were not protected from U0126-induced cell death (Figure 4j ). U0126 appeared to be able to overcome the temozolomide-induced G 2 -arrest and drive cells into G 1 -arrest (Supplementary Figure S4h) . Cells pre-treated with low-dose temozolomide were also not M A N U S C R I P T
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Environmentally induced G 1 -arrest inhibits bortezomib-induced cell death, but enhances MAPK inhibitor cytotoxicity.
As an environmental approach of inducing G 1 -arrest, we serum-starved WM164 cells under hypoxia for 24h (Figure 5a) . This environmentally induced G 1 -arrest reduced bortezomib-induced cell death (Figure 5c ), indicating that multiple methods of arresting cells in G 1 result in protection from bortezomib cytotoxicity. In contrast, environmentally induced G 1 -arrest did not protect cells from but rather increased U0126-induced cell death (Figure 5e ). This indicates that G 1 -arrest is not protective for MAPKi cytotoxicity.
C8161 cells, confluent and serum-starved for 48h, arrested in G 1 (Figure 5b ). Also this approach of environmentally induced G 1 -arrest resulted in protection from bortezomib-and temozolomideinduced cell death (Figure 5d ). Again, environmentally induced G1-arrest did not protect C8161 cells from MAPKi cytotoxicity (using high-dose U0126), but instead enhanced it (Figure 5f ).
To investigate the molecular mechanisms underlying the changes in drug sensitivity of hypoxic/starved G 1 -arrested cells, we performed immunoblotting on serum-starved WM164 cells under hypoxia for 24h or 48h (Figure 5g ). NOXA levels were decreased under hypoxia, which may contribute to the resistance to bortezomib-induced apoptosis. No changes in pERK levels relative to total ERK were seen under hypoxia (data not shown), indicating that altered MAPK signaling under hypoxia is not responsible for the enhanced sensitivity to MAPKi.
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DISCUSSION
We have established a model to study the effect of the cell cycle on drug sensitivity in real-time.
Validating this approach we confirmed that bortezomib indeed induces time-and dose-dependent G 2 -arrest resulting in death of melanoma cells, as previously shown (Hill et al., 2009 ). Here we demonstrate that bortezomib induces not only G 2 -but also G 1 -arrest and, importantly, causes apoptosis preferentially of G 2 -phase cells, likely via NOXA. Surviving G 1 -arrested cells reentered the cell cycle upon bortezomib removal, and regained sensitivity to bortezomib-induced G 2 -arrest and apoptosis. Both pharmacologically and environmentally G 1 -arrested melanoma cells are resistant to bortezomib and temozolomide, but are sensitized to MAPKi, indicating cell cycle phase-specific drug sensitivity.
Cell cycle-mediated resistance has previously been demonstrated for the taxanes, which stabilize microtubules and induce G 2 /M-arrest followed by apoptosis (Abal et al., 2003) . Indeed paclitaxel cytotoxicity is maximal in cells synchronized in G 2 /M-phase (Donaldson et al., 1994) . Moreover, pre-treatment of gastric and breast cancer cells with flavopiridol, which induces G 1 -arrest, resulted in resistance to paclitaxel (Motwani et al., 1999) . Together with our data, these findings indicate that cell cycle phase-specific drug resistance is a general escape mechanism that occurs in various cancer types and a range of chemotherapies.
We have recently shown that in drug combinations one drug can sensitize to the other but not necessarily the converse (Lucas et al., 2012 ). Here we demonstrate that reversing the order of the drug combination may impact on treatment efficacy. For example, while pre-treatment of melanoma cells with MAPKi resulted in resistance to temozolomide or bortezomib, pre-treatment with temozolomide did not result in resistance to MAPKi.
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14 Consistent with the synergistic activity of bortezomib with temozolomide against melanoma in mice ( Amiri et al., 2004) , we show that pre-treatment of melanoma cells with temozolomide, which induces G 2 -arrest, results in increased bortezomib-induced cytotoxicity, suggesting that sequential combination of bortezomib with other G 2 -phase-arresting drugs may be an effective therapeutic strategy for patients with metastatic melanoma. Supporting this idea, synchronizing myeloma cells in early S phase using reversible CDK4/CDK6 inhibition resulted in enhanced bortezomib-induced cytotoxicity compared to synchronization of cells in G 1 .
In contrast, a phase I trial with combined bortezomib and temozolomide treatment resulted in only one of 19 advanced melanoma patients achieving a partial response (Su et al., 2010) .
However, drugs in this trial were administered simultaneously. Therefore, sequential rather than a simultaneous treatment with temozolomide or other G 2 -phase targeting drugs prior to administration of bortezomib may be more effective.
Importantly, we demonstrate that while bortezomib and temozolomide effectively induce death of proliferating melanoma cells they are ineffective against either drug-induced or hypoxia/serumstarve/confluency-induced G 1 -arrested cells, as well as the G 1 -arrested core of 3D spheroids. This may explain why the combination of bortezomib and the pan-RAF inhibitor sorafenib in a recent clinical trial was ineffective for the treatment of melanoma (Sullivan et al., 2015) , as sorafenib may have quickly induced G 1 -arrest and hence neutralized the effect of bortezomib. Furthermore, drugs that specifically target cells in G 2 -phase may be universally less effective than G 1 -phase targeting drugs in vivo due to the initiation of G 0 /G 1 -arrest as part of a general stress response to drug treatment or hypoxic, nutrient-poor conditions within a tumor (Ravindran Menon et al., 2015) . However, the level of hypoxia may be important. We used moderate hypoxia (1%),
15 whereas a previous study using severe hypoxia (<0.2%) showed that hypoxic HeLa cells were more sensitive to bortezomib due to induction of ER stress pathways (Fels et al., 2008) . Hypoxia has also been shown to induce drug tolerance though various mechanisms (Shannon et al., 2003) , so hypoxia-induced G 1 -arrest may only increase sensitivity to MAPKi in the short-term. A highly proliferative tumor may also respond better than a slow growing tumor. C8161, which was most sensitive to bortezomib and temozolomide, is the fastest growing cell line and spends the least amount of time in G 1 -phase . It has previously been noted that cancer cell lines with a higher proliferation rate are more sensitive to bortezomib (Yerlikaya and Erin, 2008) , and that quiescent leukemia cells are more resistant to apoptosis induced by other proteasome inhibitors (Drexler, 1997) . Also temozolomide in lymphocytes requires proliferation to exert cell death at clinically relevant concentrations (Roos et al., 2004) .
The molecular mechanisms underlying cell cycle phase-specific resistance to bortezomib and temozolomide is not fully elucidated. We demonstrate that NOXA, known to promote bortezomib-induced apoptosis (Fernandez et al., 2005; Mohana-Kumaran et al., 2014; Podar et al., 2008; Qin et al., 2005; Reuland et al., 2012; Wolter et al., 2007) , is lower in both cycling G 1 -phase cells and hypoxia-induced G 1 -arrested cells. While NOXA is upregulated during bortezomib treatment as expected, we now demonstrate that NOXA is primarily upregulated in S/G 2 /M-but remains low in G 0 /G 1 -phase of bortezomib-treated melanoma cells. Thus it is possible that decreased levels of NOXA have a protective effect on G 1 -phase cells.
In contrast to the protective effect of G 1 -arrest on G 2 -phase targeting drugs, we show that G 1 -arrest increased sensitivity of melanoma cells to MAPKi, which induce G 1 -arrest and apoptosis (Lee et al., 2010; Smalley et al., 2006; Wroblewski et al., 2013) . This indicates that novel M A N U S C R I P T
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16 approaches that aim to block the G 1 -S transition, such as selective CDK4/6 inhibitors (Yadav et al., 2014) currently in clinical trials (Lee et al., 2015) , may be effective in combination with G 1 -but not with G 2 -phase targeting therapies. These data also further support the rationale for combining BRAF and MEK inhibitors for the treatment of melanoma, which have been shown in numerous clinical trials to improve progression-free survival compared to single-agent treatment (Flaherty et al., 2012; Long et al., 2015) . However, the emergence of resistance in response to continuous treatment with these drugs indicates that G 0 /G 1 -arrest may confer a drug tolerant phenotype that primes the cell for development of permanent resistance mechanisms and reactivation of proliferative signaling. Exposure to a sub-lethal dose of PLX4032 for 12 days (with cells remaining in G 1 -arrest) can lead to multi-drug tolerance, where cells become resistant to a subsequent treatment with the MEK inhibitor GSK1120212 or other drugs (Ravindran Menon et al., 2015) . The progression of melanoma from drug tolerance to resistance was observed in tumors of patients treated with the BRAF inhibitor dabrafenib, which subsequently became insensitive to treatment with the MEK inhibitor trametinib (Johnson et al., 2014) . Therefore, to prevent the progression of melanoma from drug tolerance to resistance it may be necessary to allow a treatment-free period in the dosing protocol to reduce the general stress response within melanoma cells responsible for development of resistance.
This study demonstrates that consideration of cell cycle-mediated resistance to bortezomib, temozolomide and MAPKi must be taken into account when planning melanoma combination therapies, timing of dosing schedules and choice of drug therapies in solid tumors. These results may extend to other drug therapies that cause cell death via cell cycle-arrest, and should be investigated in future studies.
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MATERIAL AND METHODS
Cells and cell culture
The human melanoma cell lines C8161, WM164, 1205Lu were genotypically characterized (Davies et al., 2009; Hoek et al., 2006; Smalley et al., 2007a; Smalley et al., 2007b) , grown as described (Smalley et al., 2005) (with 4% FBS instead of 2% FBS) and authenticated by STR fingerprinting (QIMR Berghofer Medical Research Institute, Herston, Australia). MelRM were grown in DMEM supplemented with 10% FBS as previously described (Zhang et al., 2001 ) and authenticated using AmpFISTR profiling (Bowden et al., 2010) .
Melanoma 3D-spheroid assays
Melanoma spheroids were prepared as described (Beaumont et al., 2015; Smalley et al., 2008; Spoerri et al., in press ). This model mimics in vivo tumor architecture and microenvironment and is used for investigating growth, invasion and viability of melanoma cells Santiago-Walker et al., 2009) . See Supplemental Materials.
Fluorescent ubiquitination-based cell cycle indicator (FUCCI)
To generate stable melanoma cell lines expressing the FUCCI constructs, and mAG-hGem (1-110) (Sakaue-Sawano et al., 2008) were subcloned into a replicationdefective, self-inactivating lentiviral expression vector system as previously described (Smalley et al., 2005) . The lentivirus was produced by co-transfection of human embryonic kidney 293T cells, high-titer viral solutions for mKO2-hCdt1 (30/120) and mAG-hGem (1/110) were prepared and used for co-transduction into three biologically and genetically well-characterized melanoma cell lines (see above) and subclones were generated by single cell sorting Spoerri et al., in press ).
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Drugs
Proteasome inhibitor bortezomib (Janssen Cilag; North Ryde, NSW, Australia), MEK1/2 inhibitor U0126 (Sigma-Aldrich, St. Louis, MO), selective BRAF inhibitor PLX4032 (Active Biochem, Maplewood, NJ). For pre-treatment, U0126 and PLX4032 doses were chosen so as to induce G 1 -arrest without significant cell death (Lee et al., 2010; Smalley et al., 2006) .
Drug sensitivity assay
MTS viability assays were conducted as described (McGowan et al., 2011) . See Supplemental
Materials.
Hypoxia and serum-starvation assay
FUCCI-WM164 cells were plated to 30% confluence in 10-cm dishes. The un-starved/normoxia control was incubated in complete medium at 21% O 2 and the serum-starved/hypoxia group in the same medium without FBS and bovine insulin at 1% O 2 (CB210, Binder, Germany). 24h later cells were observed for G 1 -arrest (FUCCI) prior to adding drugs or vehicle. After 48h of treatment live/dead cell analysis was performed.
Confluency and serum-starvation assay
FUCCI-C8161 cells were plated at a density of 2.5x10 4 (low confluency) or 3x10 5 cells/well (high confluency) in 6-well plates in normal medium. Cells were allowed to adhere and the highconfluency wells were changed to serum-free medium. Cells were allowed to grow for 48h, observed for G 1 -arrest (FUCCI), drugs were added for further 48h before live/dead cell analysis.
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Flow cytometry cell cycle, live/dead and annexin V analysis
Flow cytometry cell cycle and live/dead analysis was conducted as described (Beaumont et al., 2015; Haass et al., 2014) . Annexin V staining and analysis was performed according to manufacturers instructions. See Supplemental Materials.
Immunoblotting
Immunoblotting was conducted as described (Lucas et al., 2012) ; see Supplemental Materials. 
Confocal imaging of 3D spheroids
Confocal imaging of 3D spheroids was performed as previously described .
For detail see Supplemental Materials.
Fluorescence microscopy of 2D cultured cells
Imaging of live FUCCI cells before extraction for flow analysis:
Live FUCCI cells cultured in 6-well plates were imaged on a Nikon-300 inverted fluorescence microscope using 10x or 20x objectives, or a Delta Vision Elite microscope using a 20x objective (GE Healthcare Life Sciences, Cleveland, OH).
Imaging of live FUCCI cells for dose response assays:
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Cells were cultured in 96-well imaging plates (BD, Franklin Lakes, NJ) and imaged on a Pathway 855 high-content bioimager (BD) using a 10x objective.
Cell cycle image analysis
FUCCI-red, -green and -yellow cells in merged spheroid z-stacks or single plane 2D culture images were quantified using automated image analysis (Volocity software, Perkin Elmer, Waltham, MA) as previously described (Beaumont et al., 2015; Haass et al., 2014) .
Alternatively, images obtained on the BD Pathway 855 were analyzed using BD Attovision software, and red and green cell intensities were exported to FCS files for analysis using FlowJo (TreeStar).
Live time-lapse imaging and cell tracking
Live imaging of 2D cultured cells was performed on the Delta Vision Elite microscope with 30-minute intervals for 48-72h. Cells were maintained at 37˚C, 5% CO 2 . Movies were started approximately 30 minutes after drug addition or medium change. Cell tracking was performed using manual tracking in Volocity software. Individual cells were detected based on emitted fluorescence and cell death was ascertained by cell morphology (blebbing and loss of adherence).
Statistical analysis
For group comparisons (normal distribution) one-way ANOVA followed by Tukey's or 
